A 63-year-old man with COPD (FEV1 45% predicted, two hospitalised exacerbations in the last year) is on long-acting muscarinic antagonist (LAMA) monotherapy. He continues to have dyspnoea and exacerbations. According to the 2023 Canadian Thoracic Society pharmacotherapy guideline, what is the MOST appropriate next step?